First Horizon Advisors’s Corcept Therapeutics CORT Stock Holding History

First Horizon Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-211	Closed	-$24.1K	–	2355
2025 Q1	$24.1K	Hold	211	–	–	﹤0.01%	1251
2024 Q4	$10.6K	Buy	211 +197	+1,407%	+$10.3K	﹤0.01%	1576
2024 Q3	$648	Hold	14	–	–	﹤0.01%	2200
2024 Q2	$455	Hold	14	–	–	﹤0.01%	2211
2024 Q1	$353	Hold	14	–	–	﹤0.01%	2246
2023 Q4	$455	Hold	14	–	–	﹤0.01%	2305
2023 Q3	$381	Sell	14 -178	-93%	-$5.15K	﹤0.01%	2332
2023 Q2	$4.27K	Hold	192	–	–	﹤0.01%	1841
2023 Q1	$4.16K	Buy	192 +178	+1,271%	+$3.9K	﹤0.01%	1868
2022 Q4	$284	Hold	14	–	–	﹤0.01%	2416
2022 Q3	$0	Hold	14	–	–	﹤0.01%	2292
2022 Q2	$0	Hold	14	–	–	﹤0.01%	2393
2022 Q1	$0	Hold	14	–	–	﹤0.01%	1814
2021 Q4	$0	Hold	14	–	–	﹤0.01%	2278
2021 Q3	$0	Buy	+14	New	+$293	﹤0.01%	2290
2018 Q1	–	Sell	-19	Closed	–	–	1433
2017 Q4	$0	Buy	+19	New	+$344	﹤0.01%	1446

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Horizon Advisors's CORT Position: Q2 2025 in Review

First Horizon Advisors sold out of Corcept Therapeutics (CORT) in Q2 2025, closing a stake of 211 shares — an estimated $24.1K sold.

First Horizon Advisors first reported a position in CORT in Q4 2017 and held it in 16 quarters. The position peaked at $24.1K in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.

First Horizon Advisors reported no remaining Corcept Therapeutics position as of Q2 2025 after selling out during the quarter.
First Horizon Advisors sold 211 Corcept Therapeutics shares in Q2 2025, an estimated $24.1K.
First Horizon Advisors first reported a position in Corcept Therapeutics in Q4 2017 and held it in 16 quarters.
First Horizon Advisors's Corcept Therapeutics position peaked at $24.1K in Q1 2025.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.